Last reviewed · How we verify
Oxybutynin chloride OROS
Oxybutynin chloride OROS, marketed by Janssen Korea, Ltd., is an established product in the pharmaceutical market with a key composition patent expiring in 2028. Its key strength lies in its well-established market presence and the extended patent protection, which helps maintain its competitive edge. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Oxybutynin chloride OROS |
|---|---|
| Also known as | Lyrinel |
| Sponsor | Janssen Korea, Ltd., Korea |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants (PHASE4)
- A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. (PHASE3)
- Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence (PHASE3)
- A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxybutynin chloride OROS CI brief — competitive landscape report
- Oxybutynin chloride OROS updates RSS · CI watch RSS
- Janssen Korea, Ltd., Korea portfolio CI